Compounds
MDMA
Research notes
Context, reporting, and structured background for this dossier.
MDMA (3,4-methylenedioxymethamphetamine) is an entactogen under investigation for PTSD treatment. Lykos Therapeutics' application for FDA approval was rejected in August 2024. Related compound methylone (via Transcend Therapeutics, acquired by Otsuka in March 2026) is in Phase 3.
Related reporting
Recent SCM reporting that overlaps this dossier’s company, program, or governance record.
- Where MAPS Is Now
After the FDA rejected Lykos' MDMA therapy application, MAPS shifted toward policy, education, and the long game.
- Week in Review: The EPIsoDE Trial, a $1.2B Acquisition, and the State of State Policy
First full week roundup.
- Psychopharmacology Retracts Three Lykos MDMA Papers
The journal said authors withheld protocol violations at the MP4 study site and failed to fully declare competing interests.
Related entities
Other dossiers that help connect this page to the wider reporting record.
- MDMA-Assisted Therapy
- Lykos Therapeutics
Lykos Therapeutics is the commercial entity that took over the MDMA-assisted therapy for PTSD approval path from MAPS and remains the focal company in the FDA midomafetamine saga.
- MAPS (Multidisciplinary Association for Psychedelic Studies)
MAPS is the nonprofit organization that incubated and sponsored the modern MDMA-assisted therapy for PTSD program before the commercial approval effort moved into Lykos Therapeutics.
- FDA
The U.S. Food and Drug Administration is the gatekeeper for psychedelic drug development in the United States, from IND clearance through advisory committee review and any eventual approval or rejection.